To further study the consequences of ruxolitinib on leukemia cells in vivo, we injected human BCR-ABL+ ALL cells into NSG mice and monitored the recipient mice under imatinib, ruxolitinib, or combined imatinib/ruxolitinib treatment. Here, ABL1 is linked to leukemia.